Plain-English translation of NCT06411210 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether a medication called semaglutide, given as a weekly injection, can help young adults who have both type 1 diabetes and obesity lose weight and improve their heart and metabolic health. The study will compare semaglutide to a placebo (a dummy injection) over 12 months to see how the medication affects body fat distribution, blood sugar control, and cholesterol levels.
Young adults with type 1 diabetes who are also living with obesity face an especially high risk of heart disease in the future. Doctors want to understand whether this medication can safely help reduce that risk by addressing the obesity in this vulnerable population.
You likely qualify if…
You likely don't qualify if…
You will visit the research center at the beginning for baseline testing, which includes an MRI scan of your abdomen, a special glucose tolerance test, a body composition scan, and a high-fat meal test—all designed to measure how your body handles weight and metabolism. Then you'll be randomly assigned to receive either the weekly injection or a placebo injection for 12 months, with regular monitoring of your insulin dosing. Finally, you'll return for the same baseline tests repeated at 12 weeks, followed by a 4-week gradual stop of the medication and 2 weeks of additional monitoring.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
United States